&NA;NE 100 is a potent and selective &sgr;1-receptor antagonist with potential as an antipsychotic agent. NE 100 is currently undergoing phase II trials in Japan with Taisho. The compound may also be useful in the treatment of abnormal behaviour associated with cerebrovascular disorders (e.g. stroke) and senile dementia.NE 100 has no effect on dopamine or serotonin-related behaviour. NE 100 does, however, potently antagonise phencyclidine-induced behaviour in animal models. Selective and potent antagonism of central &sgr;-receptors may provide an alternative strategy for the treatment of schizophrenia.